{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:30:14Z","timestamp":1784809814207,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Opportunistic salpingectomy is defined as the removal of both fallopian tubes as part of a surgical procedure planned for other reasons. The goal is primary prevention of ovarian cancer. The procedure is offered to patients who are not known to be at increased risk of developing ovarian cancer. This is in contrast to high-risk patients with a germline mutation, particularly BRCA1\/2, for whom risk-reducing salpingo-oophorectomy is generally recommended. Premalignant cells and early occult cancers have been detected in RRSO specimens in the fimbrial funnel region, but not on the ovarian surface. The presence of mitoses, nuclear atypia, and staining in response to p53 mutation in these serous intraepithelial carcinomas (STIC) indicates the initial genetic changes in the fallopian tube mucosa that subsequently lead to the development of advanced peritoneal carcinomas. The identification of STICs has challenged the traditional view of the pathogenesis of the largest subset of epithelial ovarian cancers, namely the high-grade serous cancers of the ovary, fallopian tubes, and peritoneum. In a position statement published in 2015, the German Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Kommission Ovar recommended that patients be informed of the latest findings on the development and potential benefits of bilateral salpingectomy at the time of hysterectomy. This may reduce the risk of developing ovarian cancer later in life. However, the scientific evidence has not been deemed sufficient to justify a general recommendation. In the same year, the Austrian AGO published a statement recommending the broad use of opportunistic salpingectomy without reservation. This review examines the current status of molecular pathology studies, recent evidence on the clinical implications of STIC, new data on the use of opportunistic salpingectomy, and published patient outcomes since then. The question of whether the potential benefit of opportunistic salpingectomy, outweighs the potential harms associated with surgical morbidity, which have not been conclusively excluded, should be revisited in light of these recent data.<\/jats:p>","DOI":"10.1007\/s00404-025-07974-z","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T10:22:09Z","timestamp":1743762129000},"page":"1451-1459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intergroup statement: opportunistic salpingectomy\u2014molecular pathology, clinical outcomes and implications for practice (German Ovarian Cancer Commission, the North-Eastern German Society of Gynecologic Oncology (NOGGO), AGO Austria and AGO Swiss)"],"prefix":"10.1007","volume":"311","author":[{"given":"Martin","family":"P\u00f6lcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Meinhold-Heerlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Runnebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Sch\u00fcler-Toprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"7974_CR1","unstructured":"International Agency for Research on Cancer, G.G., World Health Organization (2020) Ovarian cancer statistics. [cited 2024]. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/25-Ovary-fact-sheet.pdf"},{"issue":"2","key":"7974_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80\u201387","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"7974_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P et al (2017) Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE 12(10):e0186043","journal-title":"PLoS ONE"},{"issue":"6","key":"7974_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jama.2017.21421","volume":"319","author":"JT Henderson","year":"2018","unstructured":"Henderson JT, Webber EM, Sawaya GF (2018) Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 319(6):595\u2013606","journal-title":"JAMA"},{"issue":"10290","key":"7974_CR5","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U et al (2021) Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 397(10290):2182\u20132193","journal-title":"Lancet"},{"issue":"5","key":"7974_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jogc.2016.04.084","volume":"38","author":"JN McAlpine","year":"2016","unstructured":"McAlpine JN, Tone AA, Hanley GE (2016) Opportunistic salpingectomy: we chose to act, not wait. J Obstet Gynaecol Can 38(5):425\u2013427","journal-title":"J Obstet Gynaecol Can"},{"issue":"1","key":"7974_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00404-015-3697-y","volume":"292","author":"M P\u00f6lcher","year":"2015","unstructured":"P\u00f6lcher M et al (2015) Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the kommission ovar of the AGO. Arch Gynecol Obstet 292(1):231\u2013234","journal-title":"Arch Gynecol Obstet"},{"key":"7974_CR8","unstructured":"Elektive Salpingektomie zur Pr\u00e4vention des epithelialen Ovarialkarzinoms, in Stellungnahme der Arbeitsgemeinschaft f\u00fcr Gyn\u00e4kologische Onkologie (AGO) der \u00d6sterreichischen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe (OEGGG) und der \u00d6sterreichischen Gesellschaft f\u00fcr Pathologie (\u00d6GP) (2015) https:\/\/ago-austria.at\/wp-content\/uploads\/2021\/01\/Stellungnahme_Salpingektomie_011015.pdf"},{"issue":"4","key":"7974_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM et al (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451\u2013456","journal-title":"J Pathol"},{"issue":"1","key":"7974_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","volume":"191","author":"IM Shih","year":"2021","unstructured":"Shih IM, Wang Y, Wang TL (2021) The origin of ovarian cancer species and precancerous landscape. Am J Pathol 191(1):26\u201339","journal-title":"Am J Pathol"},{"issue":"1","key":"7974_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5219","volume":"248","author":"RC Wu","year":"2019","unstructured":"Wu RC et al (2019) Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J Pathol 248(1):41\u201350","journal-title":"J Pathol"},{"issue":"1","key":"7974_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1093","journal-title":"Nat Commun"},{"issue":"23","key":"7974_CR13","doi-asserted-by":"publisher","first-page":"6310","DOI":"10.1158\/1078-0432.CCR-20-0270","volume":"26","author":"TR Pisanic 2nd","year":"2020","unstructured":"Pisanic TR 2nd et al (2020) Methylomic landscapes of ovarian cancer precursor lesions. Clin Cancer Res 26(23):6310\u20136320","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7974_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ygyno.2019.08.029","volume":"155","author":"JP Beirne","year":"2019","unstructured":"Beirne JP et al (2019) Defining the molecular evolution of extrauterine high grade serous carcinoma. Gynecol Oncol 155(2):305\u2013317","journal-title":"Gynecol Oncol"},{"issue":"1","key":"7974_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","volume":"8","author":"J Ducie","year":"2017","unstructured":"Ducie J et al (2017) Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun 8(1):990","journal-title":"Nat Commun"},{"issue":"1","key":"7974_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/path.6322","volume":"264","author":"Z Cheng","year":"2024","unstructured":"Cheng Z et al (2024) The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions. J Pathol 264(1):42\u201354","journal-title":"J Pathol"},{"issue":"1","key":"7974_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.pap.0000201826.46978.e5","volume":"13","author":"Y Lee","year":"2006","unstructured":"Lee Y et al (2006) Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 13(1):1\u20137","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"7974_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/pgp.0b013e31814b191f","volume":"27","author":"E Jarboe","year":"2008","unstructured":"Jarboe E et al (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 27(1):1\u20139","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"7974_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00428-021-03244-w","volume":"480","author":"JMA Bogaerts","year":"2022","unstructured":"Bogaerts JMA et al (2022) Recommendations for diagnosing STIC: a systematic review and meta-analysis. Virchows Arch 480(4):725\u2013737","journal-title":"Virchows Arch"},{"issue":"4","key":"7974_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/PAS.0000000000002187","volume":"48","author":"YW Chien","year":"2024","unstructured":"Chien YW et al (2024) Morphologic and molecular heterogeneity of high-grade serous carcinoma precursor lesions. Am J Surg Pathol 48(4):475\u2013486","journal-title":"Am J Surg Pathol"},{"key":"7974_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951292","volume":"12","author":"VC Linz","year":"2022","unstructured":"Linz VC et al (2022) Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: a systematic review of the literature. Front Oncol 12:951292","journal-title":"Front Oncol"},{"issue":"17","key":"7974_CR22","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek MP et al (2022) Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J Clin Oncol 40(17):1879\u20131891","journal-title":"J Clin Oncol"},{"issue":"2","key":"7974_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00404-023-06919-8","volume":"308","author":"J van der Ven","year":"2023","unstructured":"van der Ven J et al (2023) A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany. Arch Gynecol Obstet 308(2):527\u2013534","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"7974_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13048-021-00911-z","volume":"14","author":"K Tanha","year":"2021","unstructured":"Tanha K et al (2021) Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses. J Ovarian Res 14(1):153","journal-title":"J Ovarian Res"},{"issue":"5","key":"7974_CR25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ajog.2005.11.014","volume":"194","author":"AN Morse","year":"2006","unstructured":"Morse AN et al (2006) The risk of hydrosalpinx formation and adnexectomy following tubal ligation and subsequent hysterectomy: a historical cohort study. Am J Obstet Gynecol 194(5):1273\u20131276","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"7974_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00432-014-1622-6","volume":"140","author":"J Vorwergk","year":"2014","unstructured":"Vorwergk J et al (2014) Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol 140(5):859\u2013865","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"7974_CR27","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.3390\/curroncol30120739","volume":"30","author":"T Zadabedini Masouleh","year":"2023","unstructured":"Zadabedini Masouleh T et al (2023) Beyond sterilization: a comprehensive review on the safety and efficacy of opportunistic salpingectomy as a preventative strategy for ovarian cancer. Curr Oncol 30(12):10152\u201310165","journal-title":"Curr Oncol"},{"key":"7974_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2017.09.012","volume":"107","author":"LAM Van Lieshout","year":"2018","unstructured":"Van Lieshout LAM et al (2018) Opportunistic salpingectomy in women undergoing hysterectomy: results from the HYSTUB randomised controlled trial. Maturitas 107:1\u20136","journal-title":"Maturitas"},{"issue":"2","key":"7974_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jmig.2016.12.004","volume":"24","author":"RM Kho","year":"2017","unstructured":"Kho RM, Wechter ME (2017) Operative outcomes of opportunistic bilateral salpingectomy at the time of benign hysterectomy in low-risk premenopausal women: a systematic review. J Minim Invasive Gynecol 24(2):218\u2013229","journal-title":"J Minim Invasive Gynecol"},{"issue":"2","key":"7974_CR30","doi-asserted-by":"publisher","first-page":"e2147343","DOI":"10.1001\/jamanetworkopen.2021.47343","volume":"5","author":"GE Hanley","year":"2022","unstructured":"Hanley GE et al (2022) Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 5(2):e2147343","journal-title":"JAMA Netw Open"},{"issue":"8","key":"7974_CR31","first-page":"CD012858","volume":"8","author":"LAM van Lieshout","year":"2019","unstructured":"van Lieshout LAM et al (2019) Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev 8(8):CD012858","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"7974_CR32","doi-asserted-by":"publisher","first-page":"471.e1","DOI":"10.1016\/j.ajog.2014.01.003","volume":"210","author":"JN McAlpine","year":"2014","unstructured":"McAlpine JN et al (2014) Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 210(5):471.e1\u201311","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"7974_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jmig.2017.07.004","volume":"25","author":"SR Till","year":"2018","unstructured":"Till SR et al (2018) The use of opportunistic salpingectomy at the time of benign hysterectomy. J Minim Invasive Gynecol 25(1):53\u201361","journal-title":"J Minim Invasive Gynecol"},{"issue":"6","key":"7974_CR34","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/IGC.0000000000001288","volume":"28","author":"B Lander","year":"2018","unstructured":"Lander B et al (2018) Changing clinical practice: evaluation of implementing recommendations for opportunistic salpingectomy in British Columbia and Ontario. Int J Gynecol Cancer 28(6):1101\u20131107","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"7974_CR35","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1007\/s00432-023-04578-5","volume":"149","author":"IB Runnebaum","year":"2023","unstructured":"Runnebaum IB et al (2023) Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany. J Cancer Res Clin Oncol 149(10):6953\u20136966","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"7974_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.surg.2018.03.024","volume":"164","author":"G Tomasch","year":"2018","unstructured":"Tomasch G et al (2018) Would women accept opportunistic (prophylactic) salpingectomy at the time of nongynecologic surgery to prevent development of ovarian cancer? Surgery 164(5):931\u2013934","journal-title":"Surgery"},{"issue":"4","key":"7974_CR37","doi-asserted-by":"publisher","first-page":"399.e1","DOI":"10.1016\/j.ajog.2021.06.074","volume":"225","author":"RS Mandelbaum","year":"2021","unstructured":"Mandelbaum RS et al (2021) Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. Am J Obstet Gynecol 225(4):399.e1-399.e32","journal-title":"Am J Obstet Gynecol"},{"key":"7974_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143077","author":"HY Cho","year":"2021","unstructured":"Cho HY, Kyung MS (2021) Comparison of postoperative ovarian reserve function following laparoscopic hysterectomy and laparoscopic myomectomy: a prospective comparative pilot study. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10143077","journal-title":"J Clin Med"},{"issue":"1","key":"7974_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13048-023-01117-1","volume":"16","author":"Y Huang","year":"2023","unstructured":"Huang Y et al (2023) Effect of hysterectomy on ovarian function: a systematic review and meta-analysis. J Ovarian Res 16(1):35","journal-title":"J Ovarian Res"},{"issue":"3","key":"7974_CR40","doi-asserted-by":"publisher","first-page":"270 e1","DOI":"10.1016\/j.ajog.2016.10.035","volume":"216","author":"GE Hanley","year":"2017","unstructured":"Hanley GE et al (2017) The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol 216(3):270 e1-270 e9","journal-title":"Am J Obstet Gynecol"},{"issue":"7\u20138","key":"7974_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.gyobfe.2016.05.003","volume":"44","author":"G Chene","year":"2016","unstructured":"Chene G et al (2016) Current surgical practice of prophylactic and opportunistic salpingectomy in France. Gynecol Obstet Fertil 44(7\u20138):377\u2013384","journal-title":"Gynecol Obstet Fertil"},{"key":"7974_CR42","doi-asserted-by":"publisher","DOI":"10.4293\/JSLS.2018.00004","author":"DC Ding","year":"2018","unstructured":"Ding DC et al (2018) Trends of opportunistic salpingectomy. Jsls. https:\/\/doi.org\/10.4293\/JSLS.2018.00004","journal-title":"Jsls"},{"issue":"12","key":"7974_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/1940-6207.CAPR-21-0121","volume":"14","author":"PS Karia","year":"2021","unstructured":"Karia PS, Joshu CE, Visvanathan K (2021) Uptake and predictors of opportunistic salpingectomy for ovarian cancer risk reduction in the united states. Cancer Prev Res (Phila) 14(12):1101\u20131110","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"7974_CR44","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/ijgc-2023-004377","volume":"33","author":"MP Steenbeek","year":"2023","unstructured":"Steenbeek MP et al (2023) TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol. Int J Gynecol Cancer 33(6):982\u2013987","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"7974_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004514","volume":"22","author":"A Kather","year":"2025","unstructured":"Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB (2025) Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: a cost-effectiveness modeling study. PLoS Med 22(1):e1004514. https:\/\/doi.org\/10.1371\/journal.pmed.1004514","journal-title":"PLoS Med"},{"key":"7974_CR46","doi-asserted-by":"crossref","unstructured":"Falconer H et al (2015) Ovarian cancer risk after salpingectomy: a nationwide populationbased study. J Natl Cancer Inst 107(2)","DOI":"10.1093\/jnci\/dju410"},{"issue":"1","key":"7974_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/aogs.12516","volume":"94","author":"C Madsen","year":"2015","unstructured":"Madsen C et al (2015) Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand 94(1):86\u201394","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"7974_CR48","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.fertnstert.2023.11.031","volume":"121","author":"KGA Rufin","year":"2024","unstructured":"Rufin KGA et al (2024) Complications after opportunistic salpingectomy compared with tubal ligation at cesarean section: a retrospective cohort study. Fertil Steril 121(3):531\u2013539","journal-title":"Fertil Steril"},{"issue":"5","key":"7974_CR49","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.fertnstert.2015.08.004","volume":"104","author":"R Venturella","year":"2015","unstructured":"Venturella R et al (2015) Wide excision of soft tissues adjacent to the ovary and fallopian tube does not impair the ovarian reserve in women undergoing prophylactic bilateral salpingectomy: results from a randomized, controlled trial. Fertil Steril 104(5):1332\u20131339","journal-title":"Fertil Steril"},{"issue":"1","key":"7974_CR50","doi-asserted-by":"publisher","first-page":"85.e1","DOI":"10.1016\/j.ajog.2018.10.016","volume":"220","author":"E Collins","year":"2019","unstructured":"Collins E et al (2019) Menopausal symptoms and surgical complications after opportunistic bilateral salpingectomy, a register-based cohort study. Am J Obstet Gynecol 220(1):85.e1\u201385.e10","journal-title":"Am J Obstet Gynecol"},{"key":"7974_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.maturitas.2022.08.002","volume":"166","author":"ME Gelderblom","year":"2022","unstructured":"Gelderblom ME et al (2022) The effect of opportunistic salpingectomy for primary prevention of ovarian cancer on ovarian reserve: a systematic review and metaanalysis. Maturitas 166:21\u201334","journal-title":"Maturitas"},{"key":"7974_CR52","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.maturitas.2022.01.006","volume":"159","author":"ME Gelderblom","year":"2022","unstructured":"Gelderblom ME et al (2022) Stop Ovarian Cancer (STOPOVCA) young: protocol for a multicenter follow-up study to determine the long-term effects of opportunistic salpingectomy on age at menopause. Maturitas 159:62\u201368","journal-title":"Maturitas"},{"issue":"1","key":"7974_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13063-023-07244-w","volume":"24","author":"A Idahl","year":"2023","unstructured":"Idahl A et al (2023) HOPPSA update: changes in the study protocol of Hysterectomy and Opportunistic Saipingectomy, a registry-based randomized controlled trial. Trials 24(1):22","journal-title":"Trials"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-07974-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-025-07974-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-07974-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T21:01:57Z","timestamp":1745701317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-025-07974-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["7974"],"URL":"https:\/\/doi.org\/10.1007\/s00404-025-07974-z","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have declared no conflicts of interest regarding this article. Potential financial interests exist for MP: research funding, advisory board, honorarium, or travel expenses from Astra Zeneca, Glaxo Smith Kline, MSD. PW: has received research funding from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, Lilly, and honoraria from Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, and Daichii Sankyo. PW serves on the advisory boards of Amgen, AstraZeneca, MSD, GlaxoSmithKline, Novartis, Pfizer, Roche Pharma, Clovis, TEVA, Eisai, Lilly, Gilead, and Daichii Sankyo; IMH: has received support from PlantTec, Tesaro\/GSK, MSD as a member of advisory boards, from MSD, Tesaro\/GSK and Roche for venue support and unrestricted research grants from Gedeon Richter, Bayer, Jenapharm, Takeda, Storz and PlantTec.; IR: no conflict; SST: received honoraria for speakers from Pfizer, Roche, and author fees from Thieme, with the continuing education supported by GSK and Celgene; SM: Research funding, advisory board, honoraria, or travel grants: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Hubro, Immunogen, Medac, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Roche, Seagen, Sensor Kinesis, and Teva; CG: Consultant: Abbvie, AstraZeneca, Celgene, Clovis, Eisai, GSK, MSD, PharmaMar, Roche, Vifor Pharma, Sandoz; Speaker: Abbvie, Amgen, AstraZeneca, Eisai, GSK, MSD, PharmaMar, Roche, Sandoz; Direct research funding: AstraZeneca, Meda Pharma, Roche Diagnostics;Travel\/meeting support: AstraZeneca, GSK, MSD, PharmaMar, Roche, Roche Diagnostics; VHS: no conflict; AH: honoraria for speakers from AstraZeneca, Celgene, GSK, LEO Pharma, Lilly Deutschland, MedConcept GmbH, Med Update GmbH, Pfizer, MSD, PharmaMar, Pierre Fabre Pharma, Roche Pharma AG. For advisory boards and consultancy services: AstraZeneca, GSK, LEO Pharma, MSD, PharmaMar, Roche Pharma AG, Streamedup! GmbH, and Tesaro Bio Germany GmbH; JS: Research Funding: Roche Pharma, AstraZeneca, Bayer, Clovis Oncology, GlaxoSmith, Lilly, Tesaro, Iqvia, Mural, MSD; Honorary: Tesaro, GlaxoSmith, PharmaMar, AstraZeneca, Clovis Oncology, Bayer, Roche Pharma, Vifor Pharma, Hexal AG, Novartis Pharma, Eisai, Esteve Pharmaceuticals, Incyte Biosciences, Phytolife Nutrition, JenaPharm, Kyowa Kirin, Oncoinvent AS, Daiichi, Medtronic Covidien, AMGEN; Consulting: Tesaro, Merck \/Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma; GlaxoSmith, MSD, Eisai, Novocure, Oncoinvent, Intuitive Surgical, Seagan, Bayer Vital, Mundipharma, Sanofi-Aventis Deutschland GmbH, Immunogen, Tubulis GmbH, Daiichi Sankyo, Bristol Myers, Karyopharm Therpeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}